Point of Care Testing Market Size - By Product, By Technology (Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays, Agglutination Assays, Flow-Through, Solid Phase, Biosensors), By Prescription (OTC Testing, Prescription-based Testing), By Application, By End-use – Global Forecast 2023 - 2032

Point of Care Testing Market Size - By Product, By Technology (Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays, Agglutination Assays, Flow-Through, Solid Phase, Biosensors), By Prescription (OTC Testing, Prescription-based Testing), By Application, By End-use – Global Forecast 2023 - 2032

Point of Care Testing Market Size

Point Of Care Testing Market size was over USD 38.5 billion in 2022 and is poised to witness 7% CAGR from 2023 to 2032 driven by the rising prevalence of multiple medical diseases across developing countries.
 

The rising frequency of infectious illnesses and chronic ailments, such as cardiovascular diseases, particularly in India and Africa, has increased the demand for point of care testing. According to the WHO report, in 2021, around 37.7 million people suffered from HIV, with more than two-thirds of them (25.4 million) residing in developing countries, such as Africa and India, among others. Similarly, the Ebola virus disease pandemic in West Africa caused massive economical disruptions and many deaths. The diagnostic management of these illnesses relies heavily on point of care testing technologies.
 

Point of Care Testing Restraints

The rising need for timely and efficient patient management, especially in emergency settings has fueled the adoption of point of care testing (POCT) devices. The growing advancements in technology along with the surging shift towards personalized medicine has led to the rising trend of decentralizing healthcare services. Depending on the kind and nature of the sample or test, the product designs make use of a wide range of engineering applications and technologies. The rise in the overall cost of product development due to cartridge integration for increasing the connectivity between the two components.
 

COVID-19 Impact

The advent of the COVID-19 pandemic presented major challenges for clinical laboratories seeking reliable laboratory diagnostic confirmation, consequently influencing the expansion of the market. The use of POC kits in COVID-19 diagnosis expanded significantly to offer several benefits, such as minimized size, portability, simplicity, and accurate results. The FDA also approved point-of-care diagnostics for new COVID-19 illnesses, such as the Abbott ID NOW and Cepheid GeneXpert. Thus, scalable, inexpensive, and simple-to-use POC diagnostics served as an essential method to combat the pandemic, in turn.
 

Point of Care Testing Market Trends

The current trend in the point of care industry is strongly persuaded towards smart devices equipped with mobile healthcare that will significantly accelerate the progress of personalized healthcare monitoring and management. A wide range of mobile healthcare technologies, such as cell phone-based point of care technologies have grown largely preferred. For instance, in January 2022, Roche introduced the Cobas pulse system in countries that accept the CE Mark for combining professional blood glucose control with mobile digital medical capabilities to improve patient care. Moreover, the surging popularity of molecular diagnostics over conventional culture methods in obtaining timely results.
 

Point of Care Testing Market Analysis

The glucose monitoring segment in the point of care testing market is projected to reach USD 19.2 billion by 2032 attributed to the increasing adoption of portable, highly convenient, and cost-effective as well as rapid POC glucose tests. The short turnaround time of point-of-care blood glucose (BG) testing has contributed to its growing popularity over central laboratory testing. Furthermore, blood glucose POCT eliminates post-analytical and pre-analytical elements that might impact test analysis, such as transportation, multiple user handling, order verification, and delayed reporting, consequently strengthening.
 

Point of care testing market from the biosensors technology is anticipated to record more than USD 26.7 billion in revenue in 2032. Biosensors technology has gained significant prominence due to its ability to provide rapid, accurate, and on-site diagnostic information. As a result, healthcare professionals can make quick and informed decisions leading to improved patient outcomes. In January 2023, Intricon, a developer of smart miniaturized electronics-powered medical devices launched the new Biosensors Centre of Excellence to integrate its biosensor device expertise into a vertically connected entity for providing biosensor devices to the medical industry.
 

Point of care testing market from the nephrology testing segment is expected to grow at 7.2% CAGR by 2032, owing to the rising frequency of kidney failures and other associated disorders. According to the CDC report published in 2023, more than 1 in every 7 adults, approximately 35.5 million Americans suffer from chronic kidney diseases. The use of POCT in nephrology has resulted in quicker and more reliable findings, allowing earlier interventions and personalized treatment programs. Furthermore, the portability and ease of use of point of care testing devices offers testing in distant and resource-limited settings, boosting patient outcomes and lowering healthcare costs.
 

North America point of care testing market size is projected to generate more than USD 35.5 billion by 2032. Rising R&D investments and thriving private funding for healthcare infrastructure development are driving the industry expansion. Furthermore, several market participants are focused on developing testing solutions to deliver early results, consequently enhancing the regional market outlook. For instance, in May 2023, a Los Angeles-based startup, Sensible Diagnostics, developed a small, low-cost sample-to-answer device that can conduct PCR in 10 minutes, together with affordable test cartridges, with the initial focus on infectious disease testing at the point of care.
 

Point of Care Testing Market Share

The competitive analysis of the point of care testing market includes prominent companies

• Becton
• Dickinson and Company
• Abbott Laboratories
• F. Hoffmann-La Roche
• Abaxis
• ACON Laboratories
• BioMerieux SA
• Bio-Rad Laboratories Inc
• HemoCue AB (Danaher Corporation)
• Dexcom, Inc
• Medtronic Plc
• Meridian Bioscience
• Trinity Biotech
• Nova Biomedical
• OraSure Technologies
• LifeScan IP Holdings LLC
• Siemens Healthineers AG
• Accubiotech Co Ltd
• Sysmex Corporation
• Dragerwerk Ag & Co
• BioLytical Laboratories Inc.
   

Point of Care Testing Industry News

• In July 2023, Vital Biosciences launched VitalOne, a revolutionary point-of-care lab testing platform providing blood testing ubiquitously to allow doctors to conduct tests, diagnose, and treat patients during a single visit.
   

Point of care testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Product (USD Million)

• Glucose monitoring
  • Strips
  • Meters
  • Lancets
• Cardiometabolic testing products
  • Cardiac marker testing products
    • hsTnl
    • BNP
    • D-dimer
    • CK-MB
    • Myoglobin
    • Others
  • Blood gas/electrolytes testing products
  • HBA1C testing products
• Infectious disease testing products
  • Influenza testing products
  • HIV testing products
  • Hepatitis C testing products
  • Sexually transmitted disease (STD) testing products
  • Healthcare-associated infection (HAI) testing products
  • Respiratory infection testing products
  • Tropical disease testing products
  • Others
• Coagulation testing products
  • PT/INR testing products
  • Activated clotting time (ACT/APTT) testing products
• Pregnancy and fertility testing products
  • Pregnancy testing products
  • Fertility testing products
• Tumor/cancer marker testing products
• Cholesterol testing products
• Hematology testing products
• Drug-of-abuse (DoA) testing products
• Fecal occult testing products
• Urinalysis testing products
• Others

By Technology (USD Million)

• Lateral flow assays
• Dipsticks
• Microfluidics
• Molecular diagnostics
• Immunoassays
• Agglutination assays
• Flow-through
• Solid phase
• Biosensors

By Prescription (USD Million)

• OTC testing
• Prescription-based testing

By Application (USD Million)

• Cardio metabolic testing
• Infectious disease testing
• Nephrology testing
• Drug-of-abuse (DoA) testing
• Blood glucose testing
• Pregnancy testing
• Cancer biomarker testing
• Others

By End-use (USD Million)

• Hospitals
• Diagnostic centers
• Research laboratories
• Home-care settings
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Switzerland
  • The Netherlands
  • Denmark
  • Poland
  • Sweden
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • New Zealand
  • Thailand
  • Vietnam
  • Indonesia
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Turkey